{"markup":"\u003C?xml version=\u00221.0\u0022 encoding=\u0022UTF-8\u0022 ?\u003E\n    \u003Chtml version=\u0022HTML+RDFa+MathML 1.1\u0022\n    xmlns:content=\u0022http:\/\/purl.org\/rss\/1.0\/modules\/content\/\u0022\n    xmlns:dc=\u0022http:\/\/purl.org\/dc\/terms\/\u0022\n    xmlns:foaf=\u0022http:\/\/xmlns.com\/foaf\/0.1\/\u0022\n    xmlns:og=\u0022http:\/\/ogp.me\/ns#\u0022\n    xmlns:rdfs=\u0022http:\/\/www.w3.org\/2000\/01\/rdf-schema#\u0022\n    xmlns:sioc=\u0022http:\/\/rdfs.org\/sioc\/ns#\u0022\n    xmlns:sioct=\u0022http:\/\/rdfs.org\/sioc\/types#\u0022\n    xmlns:skos=\u0022http:\/\/www.w3.org\/2004\/02\/skos\/core#\u0022\n    xmlns:xsd=\u0022http:\/\/www.w3.org\/2001\/XMLSchema#\u0022\n    xmlns:mml=\u0022http:\/\/www.w3.org\/1998\/Math\/MathML\u0022\u003E\n  \u003Chead\u003E\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/d282kpwvnogo5m.cloudfront.net\/sites\/default\/files\/js\/js_itu2PgFdrjV-docKmLK8Jn5oXe_05RgvQh73eOhI_mE.js\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/mdc.sagepub.com\/sites\/all\/modules\/highwire\/highwire\/plugins\/highwire_markup_process\/js\/highwire_at_symbol.js?nznnb1\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/mdc.sagepub.com\/sites\/all\/modules\/highwire\/highwire\/plugins\/highwire_markup_process\/js\/highwire_article_reference_popup.js?nznnb1\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/d282kpwvnogo5m.cloudfront.net\/sites\/default\/files\/js\/js_I8yX6RYPZb7AtMcDUA3QKDZqVkvEn35ED11_1i7vVpc.js\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022\u003E\n\u003C!--\/\/--\u003E\u003C![CDATA[\/\/\u003E\u003C!--\n(function(i,s,o,g,r,a,m){i[\u0022GoogleAnalyticsObject\u0022]=r;i[r]=i[r]||function(){(i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)})(window,document,\u0022script\u0022,\u0022\/\/www.google-analytics.com\/analytics.js\u0022,\u0022ga\u0022);ga(\u0022create\u0022, \u0022UA-15605596-27\u0022, {\u0022cookieDomain\u0022:\u0022auto\u0022});ga(\u0022set\u0022, \u0022page\u0022, location.pathname + location.search + location.hash);ga(\u0022send\u0022, \u0022pageview\u0022);ga(\u0027create\u0027, \u0027UA-189672-26\u0027, \u0027auto\u0027, {\u0027name\u0027: \u0027hwTracker\u0027});\r\nga(\u0027hwTracker.send\u0027, \u0027pageview\u0027);\n\/\/--\u003E\u003C!]]\u003E\n\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022\u003E\n\u003C!--\/\/--\u003E\u003C![CDATA[\/\/\u003E\u003C!--\njQuery.extend(Drupal.settings, {\u0022basePath\u0022:\u0022\\\/\u0022,\u0022pathPrefix\u0022:\u0022\u0022,\u0022highwire\u0022:{\u0022markup\u0022:[{\u0022requested\u0022:\u0022full-text\u0022,\u0022variant\u0022:\u0022full-text\u0022,\u0022view\u0022:\u0022full\u0022,\u0022pisa\u0022:\u0022spmdc;13\\\/14\\\/6\u0022},{\u0022requested\u0022:\u0022long\u0022,\u0022variant\u0022:\u0022full-text\u0022,\u0022view\u0022:\u0022full\u0022,\u0022pisa\u0022:\u0022spmdc;13\\\/14\\\/6\u0022}],\u0022ac\u0022:{\u0022spmdc;13\\\/14\\\/6\u0022:{\u0022access\u0022:{\u0022reprint\u0022:true,\u0022full\u0022:true},\u0022pisa_id\u0022:\u0022spmdc;13\\\/14\\\/6\u0022,\u0022atom_uri\u0022:\u0022\u0022,\u0022jcode\u0022:\u0022spmdc\u0022}}},\u0022googleanalytics\u0022:{\u0022trackOutbound\u0022:1,\u0022trackMailto\u0022:1,\u0022trackDownload\u0022:1,\u0022trackDownloadExtensions\u0022:\u00227z|aac|arc|arj|asf|asx|avi|bin|csv|doc(x|m)?|dot(x|m)?|exe|flv|gif|gz|gzip|hqx|jar|jpe?g|js|mp(2|3|4|e?g)|mov(ie)?|msi|msp|pdf|phps|png|ppt(x|m)?|pot(x|m)?|pps(x|m)?|ppam|sld(x|m)?|thmx|qtm?|ra(m|r)?|sea|sit|tar|tgz|torrent|txt|wav|wma|wmv|wpd|xls(x|m|b)?|xlt(x|m)|xlam|xml|z|zip\u0022,\u0022trackUrlFragments\u0022:1},\u0022ajaxPageState\u0022:{\u0022js\u0022:{\u0022sites\\\/all\\\/libraries\\\/cluetip\\\/jquery.cluetip.js\u0022:1,\u0022sites\\\/all\\\/libraries\\\/cluetip\\\/lib\\\/jquery.hoverIntent.js\u0022:1,\u0022sites\\\/all\\\/libraries\\\/cluetip\\\/lib\\\/jquery.bgiframe.min.js\u0022:1,\u0022sites\\\/all\\\/modules\\\/highwire\\\/highwire\\\/plugins\\\/highwire_markup_process\\\/js\\\/highwire_at_symbol.js\u0022:1,\u0022sites\\\/all\\\/modules\\\/highwire\\\/highwire\\\/plugins\\\/highwire_markup_process\\\/js\\\/highwire_article_reference_popup.js\u0022:1,\u0022sites\\\/all\\\/modules\\\/contrib\\\/google_analytics\\\/googleanalytics.js\u0022:1,\u00220\u0022:1}}});\n\/\/--\u003E\u003C!]]\u003E\n\u003C\/script\u003E\n\u003Clink type=\u0022text\/css\u0022 rel=\u0022stylesheet\u0022 href=\u0022\/\/d282kpwvnogo5m.cloudfront.net\/sites\/default\/files\/advagg_css\/css__ce2QY63WIanKyr8eSq7eavr1XQRRmFD6ZSmwpyJi8lM__zXwFqpqmxrZOXXcd_TpBQpjuELbmIP9wBR5UuTDWAO4__YJWWMMdfCJuAFm5cUEp88OsodhO3ZA-2lzRfoBsSlk4.css\u0022 media=\u0022all\u0022 \/\u003E\n\u003Clink rel=\u0027stylesheet\u0027 type=\u0027text\/css\u0027 href=\u0027\/sites\/all\/modules\/contrib\/panels\/plugins\/layouts\/onecol\/onecol.css\u0027 \/\u003E\u003C\/head\u003E\u003Cbody\u003E\u003Cdiv class=\u0022panels-ajax-tab-panel panels-ajax-tab-panel-sageoa-tab-art\u0022\u003E\u003Cdiv class=\u0022panel-display panel-1col clearfix\u0022 \u003E\n  \u003Cdiv class=\u0022panel-panel panel-col\u0022\u003E\n    \u003Cdiv\u003E\u003Cdiv class=\u0022panel-pane pane-highwire-markup\u0022 \u003E\n  \n      \n  \n  \u003Cdiv class=\u0022pane-content\u0022\u003E\n    \u003Cdiv class=\u0022highwire-markup\u0022\u003E\u003Cdiv xmlns=\u0022http:\/\/www.w3.org\/1999\/xhtml\u0022 id=\u0022content-block-markup\u0022 xmlns:xhtml=\u0022http:\/\/www.w3.org\/1999\/xhtml\u0022\u003E\u003Cdiv class=\u0022article fulltext-view \u0022\u003E\u003Cspan class=\u0022highwire-journal-article-marker-start\u0022\u003E\u003C\/span\u003E\u003Cdiv class=\u0022section abstract\u0022 id=\u0022abstract-1\u0022\u003E\u003Ch2\u003ESummary\u003C\/h2\u003E\n            \u003Cp id=\u0022p-1\u0022\u003EThis article discusses guideline management of acute coronary syndromes (ACS), including ST elevation myocardial infarction (NSTEMI), ST-elevated myocardial infarction (STEMI), and management after ACS.\u003C\/p\u003E\n         \u003C\/div\u003E\u003Cul class=\u0022kwd-group\u0022\u003E\u003Cli class=\u0022kwd\u0022\u003EMyocardial Infarction\u003C\/li\u003E\u003C\/ul\u003E\u003Cul class=\u0022kwd-group clinical-trial\u0022\u003E\u003Cli class=\u0022kwd\u0022\u003EMyocardial Infarction\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003ECardiology\u003C\/li\u003E\u003C\/ul\u003E\u003Cp id=\u0022p-2\u0022\u003EMaarten L. Simoons, MD, Thoraxcenter, Erasmus University Medical Center, Rotterdam, The Netherlands, discussed guideline management of acute coronary syndromes (ACS).\u003C\/p\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-1\u0022\u003E\n         \u003Ch2 class=\u0022\u0022\u003ESTEMI MANAGEMENT\u003C\/h2\u003E\n         \u003Cp id=\u0022p-3\u0022\u003EACS is a spectrum of pathophysiological conditions that includes unstable angina (UA), non-ST elevation myocardial infarction (NSTEMI) and ST-elevated myocardial infarction (STEMI). The classification of the type of ACS involves measuring biomarkers of cardiac myocyte necrosis (preferably troponin T or I or, if these are not available, creatine kinase-MB). Patients with UA present with angina (either accelerating in nature or at rest) but have no rise in cardiac biomarkers. Patients with angina and elevated cardiac biomarkers have an MI and are further classified as either NSTEMI or STEMI based upon an electrocardiogram (ECG).\u003C\/p\u003E\n         \u003Cp id=\u0022p-4\u0022\u003EThe increased sensitivity of the assays used to measure necrosis has made it possible to detect very small amounts of myocardial necrosis. These enhanced detection techniques have led to an evolving definition of an MI. Under the current Universal Definition of Myocardial Infarction (2012), an MI is confirmed when there is evidence of myocardial necrosis\u2014identified by a rise and fall of necrosis markers (preferably troponin)\u2014with at least one value \u0026gt;99% of the upper reference limit in a clinical setting of symptomatic or image-verified myocardial ischemia [Thygesen K et al. \u003Cem\u003EEur Heart J\u003C\/em\u003E 2012].\u003C\/p\u003E\n         \u003Cp id=\u0022p-5\u0022\u003EThis universal definition recognizes several types of MI. The primary MI, or Type 1 MI, includes plaque rupture leading to intracoronary thrombus. In Type 2, the cause of the MI is an imbalance of oxygen supply and demand in the myocardium caused by arrhythmia, hypertrophic cardiomyopathy, severe anemia, or cardiogenic, hypovolemic, or septic shock. Type 3 MIs are characterized as cardiac death with symptoms suggestive of MI, or ST changes in the ECG or left bundle branch block in a patient for whom biomarker values are not available. Type 4 or 5 MIs are those associated with percutaneous coronary intervention or coronary artery bypass graft, respectively. Myocardial necrosis may also result from injury that is not related to myocardial ischemia (eg, trauma, cardiotoxic agents, myocarditis) and\/or other undetermined myocardial injury (eg, heart failure, pulmonary embolism, etc) [Thygesen K et al. \u003Cem\u003EEur Heart J\u003C\/em\u003E 2012].\u003C\/p\u003E\n         \u003Cp id=\u0022p-6\u0022\u003EEarly diagnosis is critical and may be achieved via onsite ECG interpretation by computer, by the ambulance staff or by phone transmission of the ECG to the hospital. Relief of chest pain and dyspnea, ECG monitoring, and immediate reperfusion therapy should follow. Prof. Simoons stressed that immediate reperfusion therapy in acute MI reduces infarct size and increases hospital as well as long-term survival [Boersma E et al. \u003Cem\u003ELancet\u003C\/em\u003E 1996]. It is also associated with lifelong benefits, with one study reporting a gain of \u223c3 years in life-expectancy [Domburg RT et al. \u003Cem\u003EEur J Prev Cardiol\u003C\/em\u003E 2012].\u003C\/p\u003E\n         \u003Cp id=\u0022p-7\u0022\u003EThe consistent delivery of early reperfusion therapy requires public awareness of MI symptoms, rapid response by physicians and ambulances to emergency calls, prehospital diagnosis (ECG), and regional arrangements to avoid delays. Prof. Simoons described the REPAIR Program (Reperfusion Acute Infarction Rotterdam) that has been in place since 1988. This program coordinates STEMI management for all of the hospitals in Rotterdam. Under this system, patients with a STEMI are either transported to one of two centers that are able to provide immediate reperfusion services (Thoraxcenter, Erasmus MC, or Maasstad ziekenhuis). If the patient does not appear to be having an infarction based upon the initial triage, they are sent to another Rotterdam hospital for observation.\u003C\/p\u003E\n         \u003Cp id=\u0022p-8\u0022\u003EFor STEMI patients, the optimal lifesaving strategy entails primary PCI plus stenting by an experienced team within 90 to 120 minutes after initial medical contact. If that is not possible, fibrinolytic therapy (fibrin-specific agent) should be started, preferably in an ambulance (\u003Ca id=\u0022xref-fig-1-1\u0022 class=\u0022xref-fig\u0022 href=\u0022#F1\u0022\u003EFigure 1\u003C\/a\u003E) [Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology. \u003Cem\u003EEur Heart J\u003C\/em\u003E 2012].\u003C\/p\u003E\n         \u003Cdiv id=\u0022F1\u0022 class=\u0022fig pos-float  odd\u0022\u003E\u003Cdiv class=\u0022highwire-figure\u0022\u003E\u003Cdiv class=\u0022fig-inline-img-wrapper\u0022\u003E\u003Cdiv class=\u0022fig-inline-img\u0022\u003E\u003Ca href=\u0022http:\/\/d282kpwvnogo5m.cloudfront.net\/content\/spmdc\/13\/14\/6\/F1.large.jpg?width=800\u0026amp;height=600\u0026amp;carousel=1\u0022 title=\u002230-Day Death Rate: Fibrinolysis Versus Primary PCI in STEMI Patients\u0022 class=\u0022fragment-images colorbox-load\u0022 rel=\u0022gallery-fragment-images-2028809737\u0022 data-figure-caption=\u002230-Day Death Rate: Fibrinolysis Versus Primary PCI in STEMI Patients\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003E\u003Cimg class=\u0022fragment-image\u0022 alt=\u0022Figure 1.\u0022 src=\u0022http:\/\/d282kpwvnogo5m.cloudfront.net\/content\/spmdc\/13\/14\/6\/F1.medium.gif\u0022\/\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cul class=\u0022highwire-figure-links inline\u0022\u003E\u003Cli class=\u00220 first\u0022\u003E\u003Ca href=\u0022http:\/\/d282kpwvnogo5m.cloudfront.net\/content\/spmdc\/13\/14\/6\/F1.large.jpg?download=true\u0022 class=\u0022highwire-figure-link highwire-figure-link-download\u0022 title=\u0022Download Figure 1.\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload figure\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u00221\u0022\u003E\u003Ca href=\u0022http:\/\/d282kpwvnogo5m.cloudfront.net\/content\/spmdc\/13\/14\/6\/F1.large.jpg\u0022 class=\u0022highwire-figure-link highwire-figure-link-newtab\u0022 target=\u0022_blank\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EOpen in new tab\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u00222 last\u0022\u003E\u003Ca href=\u0022\/highwire\/powerpoint\/13695\u0022 class=\u0022highwire-figure-link highwire-figure-link-ppt\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload powerpoint\u003C\/a\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003Cdiv class=\u0022fig-caption attrib\u0022\u003E\u003Cspan class=\u0022fig-label\u0022\u003EFigure 1.\u003C\/span\u003E \n               \u003Cp id=\u0022p-9\u0022 class=\u0022first-child\u0022\u003E30-Day Death Rate: Fibrinolysis Versus Primary PCI in STEMI Patients\u003C\/p\u003E\n            \u003Cq class=\u0022attrib\u0022 id=\u0022attrib-1\u0022\u003EReproduced from Boersma E et al. Does time matter? A pooled analysis of randomized clinical trials comparing primary percutaneous coronary intervention and in-hospital fibrinolysis in acute myocardial infarction patients. \u003Cem\u003EEur Heart J\u003C\/em\u003E 2006;27(7):779\u2013788. With permission from Oxford University Press.\u003C\/q\u003E\u003Cdiv class=\u0022sb-div caption-clear\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\n         \u003Cp id=\u0022p-10\u0022\u003EPatients who qualify for fibrinolytic therapy should receive either alteplase or tenecteplase, combined with aspirin 150 to 300 mg oral\/IV. Clopidogrel 300 mg should also be given since ticagrelor and prasugrel have not been tested for use with fibrinolysis. Anticoagulation therapy (preferably with enoxaparin) is recommended until revascularization. While there are contraindications for fibrinolytic therapy, all patients should continue to receive medical therapy in accordance with current guidelines.\u003C\/p\u003E\n      \u003C\/div\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-2\u0022\u003E\n         \u003Ch2 class=\u0022\u0022\u003EMANAGEMENT OF NSTEMI\u003C\/h2\u003E\n         \u003Cp id=\u0022p-11\u0022\u003EPatients with NSTEMI should be admitted to a chest-pain or cardiac care unit for an ECG with either ST monitoring or repeated 12-lead ECG. In addition, the risk of cardiac events and bleeding should also be assessed for each individual. Troponin (I\/T) should be measured at admission, after 6 to 9 hours, and in some patients again after 12 to 24 hours. An ECG is also appropriate at some point to assess left ventricular function.\u003C\/p\u003E\n         \u003Cp id=\u0022p-12\u0022\u003EInitial management of patients with NSTEMI should include antithrombotic therapy with unfractionated heparin and dual antiplatelet therapy with aspirin and either ticagrelor, prasugrel, or clopidogrel. Anti-ischemic therapy with \u03b2-blockers or nitrates should be utilized as appropriate. An invasive strategy may be considered to prevent recurrent ischemia and improve prognosis for patients with ACS, particularly in those with recurrent ischemia, major arrhythmia, hemodynamic instability, and multiple high-risk characteristics.\u003C\/p\u003E\n      \u003C\/div\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-3\u0022\u003E\n         \u003Ch2 class=\u0022\u0022\u003EMANAGEMENT AFTER ACS\u003C\/h2\u003E\n         \u003Cp id=\u0022p-13\u0022\u003EPreventive medical therapy after ACS includes the initiation of statins as soon as possible; \u03b2-blockers as soon as the patient is stable. Patients with left ventricular ejection fraction \u226440% also benefit from initiation of an angiotensin-converting enzyme (ACE) inhibitor (or angiotensin receptor blockers if ACE inhibition is not tolerated). Dual antiplatelet therapy with aspirin and clopidogrel\/prasugrel\/ticagrelor should be continued for 1 year (\u003Ca id=\u0022xref-fig-2-1\u0022 class=\u0022xref-fig\u0022 href=\u0022#F2\u0022\u003EFigure 2\u003C\/a\u003E). Lifestyle interventions include smoking cessation, weight control, and exercise. Patients should be assessed for diabetes and hypertension, and treated as necessary.\u003C\/p\u003E\n         \u003Cdiv id=\u0022F2\u0022 class=\u0022fig pos-float  odd\u0022\u003E\u003Cdiv class=\u0022highwire-figure\u0022\u003E\u003Cdiv class=\u0022fig-inline-img-wrapper\u0022\u003E\u003Cdiv class=\u0022fig-inline-img\u0022\u003E\u003Ca href=\u0022http:\/\/d282kpwvnogo5m.cloudfront.net\/content\/spmdc\/13\/14\/6\/F2.large.jpg?width=800\u0026amp;height=600\u0026amp;carousel=1\u0022 title=\u0022Management After ACS\u0022 class=\u0022fragment-images colorbox-load\u0022 rel=\u0022gallery-fragment-images-2028809737\u0022 data-figure-caption=\u0022Management After ACS\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003E\u003Cimg class=\u0022fragment-image\u0022 alt=\u0022Figure 2.\u0022 src=\u0022http:\/\/d282kpwvnogo5m.cloudfront.net\/content\/spmdc\/13\/14\/6\/F2.medium.gif\u0022\/\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cul class=\u0022highwire-figure-links inline\u0022\u003E\u003Cli class=\u00220 first\u0022\u003E\u003Ca href=\u0022http:\/\/d282kpwvnogo5m.cloudfront.net\/content\/spmdc\/13\/14\/6\/F2.large.jpg?download=true\u0022 class=\u0022highwire-figure-link highwire-figure-link-download\u0022 title=\u0022Download Figure 2.\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload figure\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u00221\u0022\u003E\u003Ca href=\u0022http:\/\/d282kpwvnogo5m.cloudfront.net\/content\/spmdc\/13\/14\/6\/F2.large.jpg\u0022 class=\u0022highwire-figure-link highwire-figure-link-newtab\u0022 target=\u0022_blank\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EOpen in new tab\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u00222 last\u0022\u003E\u003Ca href=\u0022\/highwire\/powerpoint\/13696\u0022 class=\u0022highwire-figure-link highwire-figure-link-ppt\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload powerpoint\u003C\/a\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003Cdiv class=\u0022fig-caption attrib\u0022\u003E\u003Cspan class=\u0022fig-label\u0022\u003EFigure 2.\u003C\/span\u003E \n               \u003Cp id=\u0022p-14\u0022 class=\u0022first-child\u0022\u003EManagement After ACS\u003C\/p\u003E\n            \u003Cq class=\u0022attrib\u0022 id=\u0022attrib-2\u0022\u003EACE-I=angiotensin-converting enzyme inhibitor; ARB= angiotensin receptor blockers.\u003C\/q\u003E\u003Cq class=\u0022attrib\u0022 id=\u0022attrib-3\u0022\u003ESource: Euro Heart Survey Programme ESC Report: Cardiovascular Disease in Europe 2006.\u003C\/q\u003E\u003Cdiv class=\u0022sb-div caption-clear\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\n         \u003Cp id=\u0022p-15\u0022\u003EIn summary, the important components of an ACS management program include\u003C\/p\u003E\n         \u003Cp\u003E\n            \u003C\/p\u003E\u003Cul class=\u0022list-simple \u0022 id=\u0022list-1\u0022\u003E\u003Cli id=\u0022list-item-1\u0022\u003E\n                  \u003Cp id=\u0022p-17\u0022\u003E\u25aa Early recognition of symptoms by the patient\u003C\/p\u003E\n               \u003C\/li\u003E\u003Cli id=\u0022list-item-2\u0022\u003E\n                  \u003Cp id=\u0022p-18\u0022\u003E\u25aa Prehospital diagnosis if possible (ambulances with ECG interpretation)\u003C\/p\u003E\n               \u003C\/li\u003E\u003Cli id=\u0022list-item-3\u0022\u003E\n                  \u003Cp id=\u0022p-19\u0022\u003E\u25aa Immediate reperfusion in STEMI (PCI or fibrinolytic)\u003C\/p\u003E\n               \u003C\/li\u003E\u003Cli id=\u0022list-item-4\u0022\u003E\n                  \u003Cp id=\u0022p-20\u0022\u003E\u25aa Intensive medical therapy\u003C\/p\u003E\n                  \u003Cp\u003E\n                     \u003C\/p\u003E\u003Cul class=\u0022list-simple \u0022 id=\u0022list-2\u0022\u003E\u003Cli id=\u0022list-item-5\u0022\u003E\n                           \u003Cp id=\u0022p-22\u0022\u003E\u00bb Antithrombotic, statin, \u03b2-blocker, ACE-inhibition\u003C\/p\u003E\n                        \u003C\/li\u003E\u003Cli id=\u0022list-item-6\u0022\u003E\n                           \u003Cp id=\u0022p-23\u0022\u003E\u00bb Revascularization in high-risk patients\u003C\/p\u003E\n                        \u003C\/li\u003E\u003C\/ul\u003E\u003Cp\u003E\n                  \u003C\/p\u003E\n               \u003C\/li\u003E\u003Cli id=\u0022list-item-7\u0022\u003E\n                  \u003Cp id=\u0022p-24\u0022\u003E\u25aa Secondary prevention\u003C\/p\u003E\n                  \u003Cp\u003E\n                     \u003C\/p\u003E\u003Cul class=\u0022list-simple \u0022 id=\u0022list-3\u0022\u003E\u003Cli id=\u0022list-item-8\u0022\u003E\n                           \u003Cp id=\u0022p-26\u0022\u003E\u00bb Abstaining from smoking in particular\u003C\/p\u003E\n                        \u003C\/li\u003E\u003Cli id=\u0022list-item-9\u0022\u003E\n                           \u003Cp id=\u0022p-27\u0022\u003E\u00bb Appropriate food, exercise\u003C\/p\u003E\n                        \u003C\/li\u003E\u003Cli id=\u0022list-item-10\u0022\u003E\n                           \u003Cp id=\u0022p-28\u0022\u003E\u00bb Management of hypertension and diabetes if present\u003C\/p\u003E\n                        \u003C\/li\u003E\u003Cli id=\u0022list-item-11\u0022\u003E\n                           \u003Cp id=\u0022p-29\u0022\u003E\u00bb Antithrombotics, statin, \u03b2-blocker, ACE-inhibition\u003C\/p\u003E\n                        \u003C\/li\u003E\u003C\/ul\u003E\u003Cp\u003E\n                  \u003C\/p\u003E\n               \u003C\/li\u003E\u003C\/ul\u003E\u003Cp\u003E\n         \u003C\/p\u003E\n      \u003C\/div\u003E\u003Cul class=\u0022copyright-statement\u0022\u003E\u003Cli class=\u0022fn\u0022 id=\u0022copyright-statement-1\u0022\u003E\u00a9 2013 MD Conference Express\u00ae\u003C\/li\u003E\u003C\/ul\u003E\u003Cspan class=\u0022highwire-journal-article-marker-end\u0022\u003E\u003C\/span\u003E\u003C\/div\u003E\u003Cspan id=\u0022related-urls\u0022\u003E\u003C\/span\u003E\u003C\/div\u003E\u003Ca href=\u0022http:\/\/mdc.sagepub.com\/content\/13\/14\/6.abstract\u0022 class=\u0022hw-link hw-link-article-abstract\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView Summary\u003C\/a\u003E\u003C\/div\u003E  \u003C\/div\u003E\n\n  \n  \u003C\/div\u003E\n\u003C\/div\u003E\n  \u003C\/div\u003E\n\u003C\/div\u003E\n\u003C\/div\u003E\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/mdc.sagepub.com\/sites\/all\/modules\/highwire\/highwire\/plugins\/highwire_markup_process\/js\/highwire_figures.js?nznnb1\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/mdc.sagepub.com\/sites\/all\/modules\/highwire\/highwire\/plugins\/highwire_markup_process\/js\/highwire_openurl.js?nznnb1\u0022\u003E\u003C\/script\u003E\n\u003C\/body\u003E\u003C\/html\u003E"}